Boston Scientific has entered into a definitive agreement to acquire Silk Road Medical, a leader in minimally invasive medical devices for carotid artery procedures with net revenue of approximately $194-198 million in 2024, for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.

Sunnyvale, California-based Silk Road Medical has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR), which was approved by the US Food and Drug Administration in 2015, demonstrating a reduced risk of stroke and other complications associated with traditional open surgery.

TCAR is a remarkable advancement in the field of vascular medicine, and we believe the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to bringing meaningful innovation to physicians caring for patients with peripheral vascular disease,” said Cat Jennings, president, Vascular, Peripheral Interventions at Boston Scientific, which expects the transaction to close in the second half of 2024.

en_GBEnglish (UK)